| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20043261 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20017750 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20038791 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20053858 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20053624 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015273 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015272 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015536 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20014966 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
| TVIS20015563 | HPV | ENSG00000171791.14 | protein_coding | BCL2 | Yes | No | 596 | P10415 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | BCL2 |
|---|---|
| DrugBank ID | DB11581 |
| Drug Name | Venetoclax |
| Target ID | BE0000246 |
| UniProt ID | P10415 |
| Regulation Type | antagonist |
| PubMed IDs | 23410971; 23291630; 28056525; 33275726; 27092880; 33199836; 31591468; 33578607 |
| Citations | Davids MS, Letai A: ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11;23(2):139-41. doi: 10.1016/j.ccr.2013.01.018.@@Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.@@King AC, Peterson TJ, Horvat TZ, Rodriguez M, Tang LA: Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Ann Pharmacother. 2017 May;51(5):410-416. doi: 10.1177/1060028016685803. Epub 2017 Jan 6.@@Castillo JJ, Treon SP: Management of Waldenstrom macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):372-379. doi: 10.1182/hematology.2020000121.@@Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A, Russell N: Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017 Mar 7;8(10):16220-16232. doi: 10.18632/oncotarget.8742.@@Emadi A, Kapadia B, Bollino D, Bhandary B, Baer MR, Niyongere S, Strovel ET, Kaizer H, Chang E, Choi EY, Ma X, Tighe KM, Carter-Cooper B, Moses BS, Civin CI, Mahurkar A, Shetty AC, Gartenhaus RB, Kamangar F, Lapidus RG: Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia. 2021 Jul;35(7):1907-1924. doi: 10.1038/s41375-020-01080-6. Epub 2020 Nov 16.@@Castillo JJ, Treon SP: What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 Nov;33(11):2555-2562. doi: 10.1038/s41375-019-0592-8. Epub 2019 Oct 7.@@Wang L, Lin N: Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report. Medicine (Baltimore). 2021 Feb 12;100(6):e24703. doi: 10.1097/MD.0000000000024703. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylpiperazines |
| SMILES | CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1 |
| Pathways | |
| PharmGKB | PA166153473 |
| ChEMBL | CHEMBL3137309 |
